Fulgent Genetics, Inc. (FLGT)
USD 18.74
(-3.6%)
USD 18.74
(-3.6%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 171.9 Million USD | -7.28% |
| 2022 | 185.39 Million USD | 83.39% |
| 2021 | 101.09 Million USD | 142.17% |
| 2020 | 41.74 Million USD | 121.48% |
| 2019 | 18.84 Million USD | 19.89% |
| 2018 | 15.72 Million USD | 15.78% |
| 2017 | 13.57 Million USD | 27.67% |
| 2016 | 10.63 Million USD | 11.73% |
| 2015 | 9.51 Million USD | 614.64% |
| 2014 | 1.33 Million USD | 0.0% |
| 2001 | 104.33 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 41.91 Million USD | -22.61% |
| 2024 Q2 | 43.4 Million USD | 3.57% |
| 2023 Q1 | 43.63 Million USD | -11.96% |
| 2023 FY | 171.9 Million USD | -7.28% |
| 2023 Q4 | 54.15 Million USD | 36.66% |
| 2023 Q3 | 39.63 Million USD | -1.83% |
| 2023 Q2 | 40.37 Million USD | -7.48% |
| 2022 Q3 | 45.63 Million USD | -7.96% |
| 2022 FY | 185.39 Million USD | 83.39% |
| 2022 Q1 | 40.61 Million USD | 5.0% |
| 2022 Q2 | 49.58 Million USD | 22.1% |
| 2022 Q4 | 49.56 Million USD | 8.6% |
| 2021 Q4 | 38.67 Million USD | 53.91% |
| 2021 FY | 101.09 Million USD | 142.17% |
| 2021 Q1 | 18.43 Million USD | 6.56% |
| 2021 Q3 | 25.12 Million USD | 33.24% |
| 2021 Q2 | 18.86 Million USD | 2.32% |
| 2020 Q4 | 17.29 Million USD | 44.96% |
| 2020 Q1 | 5.61 Million USD | 8.68% |
| 2020 Q2 | 6.9 Million USD | 23.14% |
| 2020 Q3 | 11.93 Million USD | 72.73% |
| 2020 FY | 41.74 Million USD | 121.48% |
| 2019 Q2 | 4.5 Million USD | 6.72% |
| 2019 Q3 | 4.95 Million USD | 9.85% |
| 2019 Q4 | 5.16 Million USD | 4.22% |
| 2019 FY | 18.84 Million USD | 19.89% |
| 2019 Q1 | 4.22 Million USD | 7.48% |
| 2018 Q3 | 3.85 Million USD | 0.05% |
| 2018 Q1 | 4.07 Million USD | 9.43% |
| 2018 FY | 15.72 Million USD | 15.78% |
| 2018 Q4 | 3.93 Million USD | 1.87% |
| 2018 Q2 | 3.85 Million USD | -5.35% |
| 2017 Q1 | 3.22 Million USD | 18.16% |
| 2017 FY | 13.57 Million USD | 27.67% |
| 2017 Q4 | 3.72 Million USD | 0.22% |
| 2017 Q3 | 3.71 Million USD | 27.65% |
| 2017 Q2 | 2.91 Million USD | -9.82% |
| 2016 Q3 | 3.52 Million USD | 121.57% |
| 2016 Q1 | 2.75 Million USD | -63.41% |
| 2016 Q2 | 1.59 Million USD | -42.2% |
| 2016 Q4 | 2.73 Million USD | -22.45% |
| 2016 FY | 10.63 Million USD | 11.73% |
| 2015 Q1 | 530 Thousand USD | 0.0% |
| 2015 Q2 | 663 Thousand USD | 25.09% |
| 2015 Q4 | 7.51 Million USD | 831.72% |
| 2015 Q3 | 807 Thousand USD | 21.72% |
| 2015 FY | 9.51 Million USD | 614.64% |
| 2014 FY | 1.33 Million USD | 0.0% |
| 2001 FY | 104.33 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | -15.379% |
| Prenetics Global Limited | 60.73 Million USD | -183.035% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -956.453% |
| CareDx, Inc | 277.76 Million USD | 38.112% |
| Exact Sciences Corporation | 2.06 Billion USD | 91.657% |
| Exagen Inc. | 52.29 Million USD | -228.736% |
| Inotiv, Inc. | 246.9 Million USD | 30.375% |
| Guardant Health, Inc. | 901.62 Million USD | 80.934% |
| Biodesix, Inc. | 77.41 Million USD | -122.046% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -4281.908% |
| Precipio, Inc. | 13.63 Million USD | -1160.493% |
| iSpecimen Inc. | 16.27 Million USD | -956.111% |
| Natera, Inc. | 938.98 Million USD | 81.692% |
| Aspira Women's Health Inc. | 24.11 Million USD | -612.889% |
| Standard BioTools Inc. | 113.48 Million USD | -51.474% |
| 23andMe Holding Co. | 420.73 Million USD | 59.141% |
| Castle Biosciences, Inc. | 242.78 Million USD | 29.194% |
| Personalis, Inc. | 128.14 Million USD | -34.151% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | -55.536% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -942.694% |
| OpGen, Inc. | 30.65 Million USD | -460.722% |
| T2 Biosystems, Inc. | 41.49 Million USD | -314.291% |
| Myriad Genetics, Inc. | 600.1 Million USD | 71.354% |
| ICON Public Limited Company | 755.64 Million USD | 77.25% |
| NeoGenomics, Inc. | 341.25 Million USD | 49.625% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -956.453% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 84.27% |
| RadNet, Inc. | 268.87 Million USD | 36.066% |
| MDxHealth SA | 71.25 Million USD | -141.251% |
| Psychemedics Corporation | 11.33 Million USD | -1416.728% |
| Illumina, Inc. | 3.81 Billion USD | 95.492% |
| Check-Cap Ltd. | 19.28 Million USD | -791.305% |
| Twist Bioscience Corporation | 354.18 Million USD | 51.464% |
| DarioHealth Corp. | 62.17 Million USD | -176.496% |
| Sera Prognostics, Inc. | 39.91 Million USD | -330.659% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -1533.973% |
| OPKO Health, Inc. | 574.68 Million USD | 70.087% |
| Medpace Holdings, Inc. | 187.68 Million USD | 8.405% |
| Neogen Corporation | 405.23 Million USD | 57.579% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -1368.178% |
| Prenetics Global Limited | 60.73 Million USD | -183.035% |
| Mainz Biomed B.V. | 27.15 Million USD | -533.07% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -1861.313% |
| Trinity Biotech plc | 46.49 Million USD | -269.73% |
| Neuronetics, Inc. | 82.25 Million USD | -108.981% |
| Sotera Health Company | 300.46 Million USD | 42.787% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -1861.313% |